Presentation is loading. Please wait.

Presentation is loading. Please wait.

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

Published byMorgan Lawson Modified over 6 years ago

Similar presentations

Presentation on theme: "From: Unmasking Masks in Makkah: Preventing Influenza at Hajj"— Presentation transcript:

1 From: Unmasking Masks in Makkah: Preventing Influenza at Hajj
Figure 1. Comparison between mask and control groups in randomized controlled trials. Abbreviations: CI, confidence interval; df, degrees of freedom; M-H, Mantel–Haenszel. From: Unmasking Masks in Makkah: Preventing Influenza at Hajj Clin Infect Dis. 2012;54(1): doi: /cid/cir826 Clin Infect Dis | © The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please 1

Download ppt "From: Unmasking Masks in Makkah: Preventing Influenza at Hajj"

Similar presentations

To enhance students ability to interpret data in charts and graphs To discuss basic concepts in epidemiology and science.

To enhance students ability to interpret data in charts and graphs To discuss basic concepts in epidemiology and science.
From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
Figure 1 The spatial and temporal distribution of diarrhoea rates

Figure 1 The spatial and temporal distribution of diarrhoea rates
Figure 1. Flow diagram of participants recruited into the study.

Figure 1. Flow diagram of participants recruited into the study.
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Period–cohort diagram.

Figure 1. Period–cohort diagram.
From: Political Leadership and Power Redistribution

From: Political Leadership and Power Redistribution
Figure 1. The Modified Dual Pathway Model.

Figure 1. The Modified Dual Pathway Model.
Figure 1. Disposition of study participants, by group. Data are no

Figure 1. Disposition of study participants, by group. Data are no
Figure 1. Forest plot: overall estimate

Figure 1. Forest plot: overall estimate
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Table 5 Village Characteristics Based on the Census of India 1991, by Mandate during which a First SHG was Created in the Village From: Public Good Provision.

Table 5 Village Characteristics Based on the Census of India 1991, by Mandate during which a First SHG was Created in the Village From: Public Good Provision.
Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.

Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.
Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)
Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.

Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.

Similar presentations

Ads by Google